Mead Enfamil Sales Buoy Bristol-Myers Nutritionals In Q2
This article was originally published in The Tan Sheet
Executive Summary
Increased spending on consumer ads and promos for Enfamil infant formula helped the brand post worldwide sales gains of roughly 8% to $172 mil. for the second quarter, Bristol-Myers Squibb's Mead Johnson division said July 25.
You may also be interested in...
Mead DHA/ARA-Fortified Infant Formula Slated For February Release
Mead Johnson Nutritionals' Enfamil LIPIL, an infant formula fortified with ARA and DHA fatty acid oils, will be priced in the U.S. at a 10%-15% premium to the line's Enfamil with Iron product, the firm said
Mead DHA/ARA-Fortified Infant Formula Slated For February Release
Mead Johnson Nutritionals' Enfamil LIPIL, an infant formula fortified with ARA and DHA fatty acid oils, will be priced in the U.S. at a 10%-15% premium to the line's Enfamil with Iron product, the firm said
Mead DHA/ARA-Fortified Infant Formula Slated For February Release
Mead Johnson Nutritionals' Enfamil LIPIL, an infant formula fortified with ARA and DHA fatty acid oils, will be priced in the U.S. at a 10%-15% premium to the line's Enfamil with Iron product, the firm said